CAMBRIDGE, Mass.—June 27, 2011 — FORMA Therapeutics announced today that it entered into an agreement granting Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), exclusive worldwide rights to acquire a pre-clinical small molecule program against a single undisclosed cancer target.
Related Posts
AI chip startup Tenstorrent more than doubles its valuation to $6.2 billion in funding round
- 19 10 2026
- |
Fintech platform iCapital plans more Singapore hires even as AI takes on 75% of coding work
- 16 10 2026
- |
Roblox CEO, Singapore Fund Join $100 Million Round in UK Quantum Firm
- 08 10 2026
- |
Revolut to open new Singapore office; will invest S$350 million and grow staff to 300 here
- 08 10 2026
- |
